makes sense, it would hardly be worthwhile getting approval for the old formulation, may as well just license or acquire the new formulation.
raises a couple of questions regarding the upcoming allcomers trial (CPACS - Cardio protective anti cancer synergy).
1. Is trial design targeting a tumour agnostic approval for CPACS RC220 (new formulation)?
2. As the CPACS trial is in combo with Doxorubicin (largest anthracycline combo opportunity), if approved would this allow Bisantrene be used off-label with other anthracyclines?
3. Does the new combination therapy of Bis + Dox allow for a combo patent?
4. Does a combo patent allow for reimbursement of Dox treatment at patent protected pricing rather than generic pricing?
5. If Bisantrene protects the heart and provides anti cancer synergy, will the lifetime Dox limit in combo allow to be increased?
Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-3
-
- There are more pages in this discussion • 218 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $210.2M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.28 | $1.20 | $129.7K | 106.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1982 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 2230 | 1 |
View Market Depth
| Last trade - 16.10pm 02/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |